Sunshine Act

CMI/Compas conducted research to gauge and compare perceptions of the Sunshine Act – including understanding of reportable and exempt items – from two perspectives: physicians and pharma industry (clients/partners). This research discovered distinct viewpoints:

  • Physicians would benefit from understanding what items are reportable and what items are exempt
  • Pharma Industry should not back away from providing valuable materials to PCPs, as they are still viewed as beneficial by physicians
  • By using visual aids, such as the CMI/Compas proposed exempt/reportable emblems, Pharma can assist physicians in quickly identifying what is reportable and what is exempt

View full results of the study here

View a list of the top pharma companies’ Sunshine Act policies here

PM360 The Sunshine Act’s Crackdown on Medical Reprints – What Pharma Can Do About It
– Article by CMI/Compas experts about the impact of The Sunshine Act on reprint marketing

The Sunshine Act Infographic
– A visual representation of the law and what is reportable

For more information on how CMI/Compas can guide you, contact Lindsay Dinan at

If you’d like to receive future insights and news from us please share your contact information and select the information you’d like to receive

First Name* Last Name*
Email* Title
Company Phone
Scoop: A daily summary of the most current healthcare and tech news, with a small dash of snarkInsider Scoop: A monthly recap of the most important news in healthcare and publishingCustomer Insights: Reports only CMI/Compas can provideThought Leadership:- POVs and whitepapers with insights only CMI/Compas can provide, sent anytime a hot topic hitsMarketing/Products: Up-to-the-minute updates on our latest products and services